Neurological Disease Overview

Principles

Definition

Neurological disease is a broad academic and clinical field dedicated to the study, diagnosis, treatment, and prevention of disorders affecting the nervous system, including the brain, spinal cord, and peripheral nerves. This interdisciplinary area investigates the etiology, pathophysiology, and clinical manifestations of conditions such as neurodegenerative diseases, stroke, epilepsy, and neuromuscular disorders, aiming to advance understanding and improve patient outcomes.

Ontological type

Pathophysiological Mechanisms

Diagnostic Approaches

Therapeutic Strategies

Key developments

Key Figures

Clinical-Pathological Integration era

Norman Geschwind, a central figure in the late 1960s–1980s, reframed language, memory, and other cognitive syndromes as disconnection phenomena tied to specific white matter tracts, promoting clinicopathological correlation and a network-based view of neurological disease. Robert Katzman championed Alzheimer's disease as a discrete pathology by linking clinical dementia to characteristic neuropathology—amyloid plaques and neurofibrillary tangles—and by advocating standardized criteria that sharpen diagnostic and prognostic relevance. Peter Davies and colleagues advanced postmortem, regionally precise pathology studies, while John Trojanowski and Virginia Lee integrated tau, beta-amyloid, and later alpha-synuclein pathologies with clinical syndromes, underlining how molecular substrates map onto specific clinical trajectories. David A. Bennett and collaborators in the 1990s applied quantitative clinicopathology to aging brains, highlighting mixed pathologies and selective vulnerability that reframed dementia prognosis and clinical trial targets.

Molecular-Driven Translation era

Justin C. McArthur [1] emerges as a leading neurologist during the Molecular-Driven Translation era, with affiliations at Harvard University [3] and University of California, San Francisco [4]. This work by McArthur [1] introduced Updated research nosology for HIV-associated neurocognitive disorders [6], standardizing classification and accelerating translational priorities in this era. Karen Marder [2] emerges as a leading figure in this era, with affiliations at Harvard University [3] and Johns Hopkins University [5]. As a co-author on Updated research nosology for HIV-associated neurocognitive disorders [6], Marder [2] helped refine diagnostic frameworks for HIV-associated neurocognitive disorders, enabling molecular insights to inform translational trial design during this era.

Multimodal Precision Neurology era

Frederik Barkhof [1] is a distinguished neurologist whose work during this era spans institutions such as Harvard University [3] and the Massachusetts Institute of Technology [4]. One of his key contributions, grounded in the 2014 paper Defining the clinical course of multiple sclerosis [7], advanced standardized phenotyping and longitudinal frameworks to map MS trajectories, illustrating the era's emphasis on real-world disease mapping. Gary Cutter [2] is a prominent figure with affiliations at University of California, San Francisco [5] and Stanford University [6] during this era. His key contributions, as highlighted by the 2014 paper Defining the clinical course of multiple sclerosis [7], include cross-modal analytics to characterize disease trajectories and inform network-based targets for precision neurology.